Hologic announced that it has agreed to acquire Biotheranostics – a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers – for approximately $230 million, according to a news release from Hologic.
Both of Biotheranostics’ tests are PCR (polymerase chain reaction)-based gene expression tests that have been validated in large studies in areas of oncology, according to Hologic. The BCI test is included in several clinical practice guidelines for breast cancer.
San Diego-based Biotheranostics generated approximately $33 million of revenue in calendar 2020.
Hologic said the acquisition is expected to close in February of 2021, subject to antitrust clearance and other customary closing conditions.
